Drug Profile

SON 1410

Alternative Names: IL18-FHAB-IL12; SON-1410

Latest Information Update: 10 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sonnet BioTherapeutics Holdings, Inc
Class Antineoplastics; Interleukins; Recombinant fusion proteins
Mechanism of Action T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Malignant melanoma
Research Renal cancer

Most Recent Events

30 Aug 2022 Sonnet BioTherapeutics Holdings announces intention to submit IND in Malignant melanoma in the second half of 2022 (Date)
30 Aug 2021 Early research in Renal cancer in USA (Parenteral) before August 2021
30 Aug 2021 Preclinical trials in Malignant melanoma in USA (Parenteral) before August 2021

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com